Carmel Capital Partners’s AbbVie ABBV Stock Holding History

Carmel Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$304K	Hold	1,210	–	–	0.1%	101
2026 Q1	$263K	Buy	1,210 +68	+6%	+$15.1K	0.1%	101
2025 Q4	$261K	Sell	1,142 -807	-41%	-$184K	0.09%	98
2025 Q3	$451K	Sell	1,949 -1,633	-46%	-$333K	0.19%	77
2025 Q2	$665K	Sell	3,582 -145	-4%	-$26.9K	0.23%	78
2025 Q1	$781K	Sell	3,727 -19	-0.5%	-$3.69K	0.31%	67
2024 Q4	$666K	Sell	3,746 -306	-8%	-$56.3K	0.27%	69
2024 Q3	$800K	Sell	4,052 -54	-1%	-$10.1K	0.31%	66
2024 Q2	$704K	Buy	4,106 +45	+1%	+$7.45K	0.3%	66
2024 Q1	$740K	Hold	4,061	–	–	0.31%	67
2023 Q4	$629K	Sell	4,061 -589	-13%	-$85.9K	0.32%	66
2023 Q3	$693K	Buy	4,650 +491	+12%	+$72.1K	0.31%	68
2023 Q2	$560K	Buy	4,159 +22	+0.5%	+$3.23K	0.29%	66
2023 Q1	$659K	Sell	4,137 -451	-10%	-$69K	0.39%	60
2022 Q4	$741K	Buy	4,588 +775	+20%	+$119K	0.51%	48
2022 Q3	$512K	Buy	3,813 +117	+3%	+$16.8K	0.49%	56
2022 Q2	$566K	Buy	3,696 +342	+10%	+$52.3K	0.53%	59
2022 Q1	$544K	Buy	3,354 +302	+10%	+$43.9K	0.45%	60
2021 Q4	$413K	Buy	+3,052	New	+$361K	0.31%	67

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Carmel Capital Partners's ABBV Position: Q2 2026 in Review

Carmel Capital Partners held its AbbVie (ABBV) position steady in Q2 2026 at 1,210 shares worth $304K. The position accounts for 0.1% of the portfolio, ranked #101.

Carmel Capital Partners first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. The position peaked at $800K in Q3 2024. 4,216 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Carmel Capital Partners held 1,210 shares of AbbVie worth $304K as of Q2 2026.
Carmel Capital Partners left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.1% of Carmel Capital Partners's portfolio in Q2 2026, its #101 holding.
Carmel Capital Partners first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
Carmel Capital Partners's AbbVie position peaked at $800K in Q3 2024.
4,216 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Carmel Capital Partners's 13F filing for Q2 2026, filed 30 Jul 2026.